Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
77 hedge funds and large institutions have $127M invested in Neos Therapeutics, Inc in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 15 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
6% less funds holding
Funds holding: 82 → 77 (-5)
13% less capital invested
Capital invested by funds: $146M → $127M (-$18.6M)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
87% less call options, than puts
Call options by funds: $95K | Put options by funds: $708K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$6.42M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$5.62M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$3.14M |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$3.14M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.93M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
-$3.16M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.06M |
| 4 |
HCS
Harvest Capital Strategies
San Francisco,
California
|
-$2.24M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.14M |
NEOS Hedge Fund Activity: Q1 2018 in Review
77 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q1 2018, worth a combined $127M — down 13% from $146M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of NEOS and 10 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 29 added.
The largest buyer was Lyon Street Capital, adding an estimated $6.42M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $3.93M sold.
- 77 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q1 2018, down from 82 in Q4 2017.
- Funds reported $127M of Neos Therapeutics, Inc stock for Q1 2018, down 13% quarter-over-quarter.
- 10 funds opened new Neos Therapeutics, Inc positions in Q1 2018 and 15 closed out, a net change of -5 holders.
- The largest Neos Therapeutics, Inc buyer in Q1 2018 was Lyon Street Capital, an estimated $6.42M added.
- The largest Neos Therapeutics, Inc seller in Q1 2018 was Oxford Asset Management, an estimated $3.93M sold.
Based on aggregated 13F filings for Q1 2018.